

## Commercial/Healthcare Exchange PA Criteria

*Effective: March 2008*

**Prior Authorization:** Eletriptan

**Products Affected:** Relpax (eletriptan) oral tablets, Eletriptan oral tablets

**Medication Description:**

Eletriptan has high affinity for 5-HT<sub>1</sub> receptor subtypes, more specifically those receptors located on intracranial blood vessels, and acts as a receptor agonist at those sites. Two theories exist to explain the 5-HT<sub>1</sub> receptor agonists in migraine headaches: activation of 5-HT<sub>1</sub> vasoconstricts intracranial blood vessels and correlates to relief of migraine headaches; activation of 5-HT<sub>1</sub> receptors on sensory nerve endings inhibits pro-inflammatory response in the trigeminal system.

**Covered Uses:** Eletriptan is indicated for the acute treatment of migraine with or without aura in adults.

**Exclusion Criteria:**

1. Prevention of migraine attacks
2. Cluster headache
3. Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal's angina
4. Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders
5. History of stroke, transient ischemic attack (TIA), or history or current evidence of hemiplegic or basilar migraine because these patients are at a higher risk of stroke
6. Peripheral vascular disease
7. Ischemic bowel disease
8. Uncontrolled hypertension

**Required Medical Information:**

1. Diagnosis
2. Previous therapies tried and failed

**Age Restrictions:** 18 years of age and older

**Prescriber Restrictions:** N/A

**Coverage Duration:** 12 months

**Other Criteria:**

1. Patient has a documented intolerance to, or treatment failure of an adequate trial of TWO of the following medications: naratriptan, almotriptan, frovatriptan, sumatriptan, rizatriptan, or zolmitriptan



**References:**

1. Product Information: RELPAX(R) oral tablets, eletriptan hydrobromide oral tablets. Roerig (per FDA), New York, NY, 2013.

2. Product Information: Eletriptan hydrobromide oral tablets, eletriptan hydrobromide oral tablets. Amneal Pharmaceuticals LLC (per DailyMed), Bridgewater, NJ, 2018.

**Policy Revision history**

<b>Rev #</b>	<b>Type of Change</b>	<b>Summary of Change</b>	<b>Sections Affected</b>	<b>Date</b>
1	New Policy	All	All	3/2008
2	Template update	Reformatted from old to new CCI Template  CCI P&T Review History: 3/08, 6/08, 9/09, 9/10, 12/11, 10/12, 10/13, 10/14, 11/15, 5/16, 11/16, 5/17, 4/17, 5/18, 5/19  CCI Revision Record: 8/11, 6/13, 8/13, 4/16, 11/16, 5/18  Added Mechanism of Action  Updated Exclusion Criteria to match FDA Label  Updated Reference	All	6/5/2020

Last Res.6.5.2020



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.